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Fibrillins 1-3 are stromal extracellular matrix proteins that play important roles in regulating 18 
TGFβ activity, which stimulates fibroblasts to proliferate and synthesise collagen. In the 19 
developing ovary the action of stroma is initially necessary for formation of the ovigerous 20 
cords and subsequently for the formation of follicles and the surface epithelium of the ovary.  21 
FBN3 is highly expressed only in early ovarian development and then it declines. In contrast, 22 
FBN1 and 2 are up regulated in later ovarian development.  We examined the expression of 23 
FBN1-3 in bovine and human fetal ovaries. We used cell dispersion and monolayer culture, 24 
cell passaging and tissue culture.  Cells were treated with growth factors, hormones or 25 
inhibitors to assess the regulation of expression of FBN1-3.  When bovine fetal ovarian tissue 26 
was cultured, FBN3 expression declined significantly. Treatment with TGFβ-1 increased 27 
FBN1 and FBN2 expression in bovine fibroblasts, but did not affect FBN3 expression. 28 
Additionally, in cultures of human fetal ovarian fibroblasts (9-17 weeks gestational age) the 29 
expression of FBN1 and FBN2 increased with passage whereas FBN3 dramatically decreased. 30 
Treatment with activin A and a TGFβ family signalling inhibitor, SB431542, differentially 31 
regulated expression of a range of modulators of TGFβ signalling and of other growth factors 32 
in cultured human fetal ovarian fibroblasts suggesting that TGFβ signalling is differentially 33 
involved in regulation of ovarian fibroblasts. Additionally since the changes in FBN1-3 34 
expression that occur in vitro are those that occur with increasing gestational age in vivo, we 35 
suggest that the fetal ovarian fibroblasts mature in vitro. 36 
 37 
 38 
Keywords: Stroma, bovine, human, fetal ovary, fibrillin, TGFβ-1, activin A, SB431542. 39 
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Fibroblasts or stromal cells are of mesenchymal origin (Wong et al. 2007) and are a major 43 
cell type present in the stroma of many organs (Birchmeier & Birchmeier 1993). They play 44 
an important role in the production and deposition of collagen in tissues (Varga et al. 1987; 45 
Christner & Ayitey 2006) and ensure proper organ development and function (Saxen & 46 
Sariola 1987; Birchmeier & Birchmeier 1993).  Perturbations within the stroma can result in 47 
defects in the functions of organs such as pulmonary fibrosis (Rock et al. 2011), cardiac 48 
fibrosis (Chen et al. 2000), renal fibrosis (Ito et al. 1998) and polycystic ovary syndrome 49 
(PCOS) (Hughesdon 1982).  50 
Fibroblasts are activated by a pro-fibrotic cytokine, TGFβ (Roberts et al. 1986; Chen 51 
et al. 2000; Raja-Khan et al. 2014). There are three TGFβs that are secreted as inactive latent 52 
homodimeric complexes of precursor molecules each consisting of a signal peptide, a 53 
latency-associated peptide (LAP) and a mature peptide (Saharinen et al. 1999). These LAPs 54 
form covalent disulphide bonds with other chaperone proteins called latent TGFβ binding 55 
proteins (LTBPs) (Saharinen et al. 1999), specifically LTBP1, LTBP3 and LTBP4 (Isogai et 56 
al. 2003). LTBPs also play a role in regulating the secretion of latent TGFβ from cells and 57 
targeting latent TGFβ to the extracellular matrix (ECM) (Taipale et al. 1994; Isogai et al. 58 
2003), where glycoproteins called fibrillins are present.  59 
Fibrillins are major structural components in stromal ECM (Ramirez & Pereira 1999). 60 
In addition to their structural function, they regulate growth factor/cytokine activity by 61 
binding LTBPs 1 to 4 (Isogai et al. 2003; Zilberberg et al. 2012) and thus sequestering latent 62 
TGFβ in the ECM (Chaudhry et al. 2007). This is important for the regulation of TGFβ 63 
activation and bioavailability in the ECM (Saharinen et al. 1999; Chaudhry et al. 2007) and 64 
hence for stromal fibroblast function. TGFβ is only released from the ECM and activated via 65 
proteolytic cleavage (Saharinen et al. 1999). Activated TGFβ can then activate fibroblasts to 66 
proliferate and synthesise ECM proteins such as collagens and fibronectin (Fine & Goldstein 67 
1987; Varga et al. 1987; Leask & Abraham 2004). In 2004 another member of the fibrillin 68 
family, fibrillin 3 was discovered (Corson et al. 2004). The expression of the FBN3 gene was 69 
shown to be significantly higher in fetal compared to adult tissues of the same organs (Corson 70 
et al. 2004; Sabatier et al. 2010; Hatzirodos et al. 2011). Furthermore, in addition to humans, 71 
FBN3 is expressed in cows, sheep and chickens, but not in rodents (Corson et al. 2004).  72 
Recent studies have proposed a new model of mammalian ovarian development 73 
which emphasises the importance of stromal penetration and expansion as a crucial processes 74 
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in the developing fetal bovine and human ovaries (Hummitzsch et al. 2013; Heeren et al. 75 
2015; Hummitzsch et al. 2015). The stromal tissue first penetrates the developing ovary from 76 
the mesonephros and whilst doing so it subdivides and thus partitions the oogonia and the 77 
precursor gonadal-ridge epithelial (GREL) cells of the ovary into ovigerous cords. It then 78 
segregates the ovigerous cords into smaller groups of cells thus contributing to the formation 79 
of follicles. Finally it penetrates to just below the surface of the ovary before spreading 80 
laterally, thus isolating some GREL cells at the surface of the ovary.  These GREL cells then 81 
begin to form an epithelium on the surface. Throughout ovary development the stroma 82 
expresses fibrillin genes but different ones at different times. In the bovine and human, FBN1 83 
is expressed during fetal ovarian development and increases significantly in the adult ovary 84 
(Hatzirodos et al. 2011). FBN2 is also expressed in fetal ovaries but declines in the later 85 
stages of bovine fetal ovarian development and increases in the adult bovine ovary. In 86 
humans, FBN2 is expressed during fetal ovarian development but is very low in the adult 87 
ovary (Hatzirodos et al. 2011). FBN3 is highly expressed in the early bovine and human fetal 88 
ovary, however its expression declines and is undetectable in adult bovine and human ovaries 89 
(Hatzirodos et al. 2011). Histochemical localisation of fibrillin 3 revealed an extensive 90 
network of fibrillin 3 fibres in the stromal compartment as it penetrates between ovigerous 91 
cords in fetal bovine and human ovaries (Hatzirodos et al. 2011; Hummitzsch et al. 2013). 92 
These findings suggest that fibrillin 3 plays a crucial role in the fetal ovary during early ovary 93 
development, when stromal tissue is expanding from the mesonephros into the developing 94 
ovary (Hatzirodos et al. 2011; Hummitzsch et al. 2013) but as development progresses 95 
fibrillin 1 in particular becomes more important.  96 
Although the stromal matrix protein fibrillin-3 appears to have an important role early 97 
in fetal development, in contrast to all other fibrillins, LTBPs and TGFβ molecules, there is 98 
very little known about its regulation or function. A recent study by Davis et al. (2014) 99 
identified the promoters of the human fibrillin genes and the transcription factors that bind to 100 
these promoters (Davis et al. 2014). This study was heavily biased to adult tissues present in 101 
the FANTOM database at that time, thus limiting the information about the promoter of 102 
FBN3 and identification of potential transcription factor binding motifs present within this 103 
promoter.  Interestingly it was found that the transcription factor binding motifs in the FBN3 104 
promoter do not overlap with those of other two fibrillin genes (Davis et al. 2014). This 105 
would be consistent with the differential expression of the fibrillin genes seen in ovaries 106 
(Hatzirodos et al. 2011).  107 
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The FBN3 gene may be associated with the occurrence of PCOS (Urbanek et al. 108 
2007). The PCOS ovary phenotype has the hallmarks of increased TGFβ activity with 109 
expanded stroma and collagen deposition (Hughesdon 1982).  Additionally the behaviour of 110 
the specialised stromal thecal cells is different, with increased steroidogenic activity (Nelson 111 
et al. 1999; Polla et al. 2003). Thus aberrant FBN3 activity during fetal development could be 112 
related to the altered stroma phenotype in the PCOS ovary (Hatzirodos et al. 2011; Raja-113 
Khan et al. 2014).  In this study our goals were to determine the factors that affect FBN1-3 114 
expression in human and bovine fetal ovaries. 115 
 116 
 117 
Materials and Methods 118 
 119 
Bovine fetal tissues 120 
 121 
Bovine fetal ovaries from a range of gestational ages were collected from fetuses of Bos 122 
taurus cows from a local abattoir (Thomas Foods International, Murray Bridge, SA, 123 
Australia). The crown-rump-length of the fetuses was measured to determine the approximate 124 
ages of fetuses (Russe 1983) and the fetal ovaries were transported on ice in Hank’s 125 






; Sigma-Aldrich Pty Ltd, Castle 126 
Hill, NSW, Australia) to the laboratory. The connective tissue surrounding the fetal ovaries 127 
was removed and a small portion of the ovaries was excised and frozen at -80ᵒC for 128 
subsequent RNA extraction. The ovaries were rinsed once in 70% ethanol and twice in 129 
HBSS
+/+
 and then dissected into small pieces and minced with a scalpel. The fetal ovaries 130 
were digested in 3-5 ml of 1 mg/ml collagenase type I (GIBCO/ Life Technologies Australia 131 
Pty Ltd, Mulgrave, VIC, Australia) in HBSS
+/+ 
at 37ºC shaking at 150 rpm. The durations of 132 
digestion for the fetal ovaries depended on the crown-rump lengths of the fetuses. After the 133 
first digestion, the samples were centrifuged at 1500 rpm for 5 min and the supernatant was 134 
removed. The samples were then digested in 2 ml of 0.025% trypsin/EDTA (GIBCO/Life 135 







Aldrich) for 5 min at 37ºC at 150 rpm. After centrifugation at 1500 rpm for 5 min, the cell 137 
pellets were resuspended in DMEM/F12 medium containing 5% FCS, 1% penicillin and 138 
streptomycin sulphate, and 0.1% fungizone (all GIBCO/Life Technologies) and the cells 139 
were dispersed further by pipetting up and down. The fetal fibroblasts were cultured in 6-well 140 
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plates or 10 cm petri dishes at 38.5ºC and 5% CO2 until confluent. Once the fetal fibroblast 141 
cultures were confluent, the cells were detached by treatment with 0.25% trypsin/EDTA, the 142 
total number of viable cells was estimated with the trypan blue method using a 143 
haemocytometer and the cells subsequently stored in liquid nitrogen for later use.   144 
 145 
Human fetal tissues 146 
 147 
Morphologically normal human fetal ovaries (9-17 weeks gestation) were obtained following 148 
medical termination of pregnancy. Maternal consent was obtained and the study was 149 
approved by the Lothian Research Ethics Committee (ref 08/S1101/1). Gestational age of the 150 
fetuses was determined by ultrasound scan and by direct measurement of the fetal foot length. 151 
Extraneous tissue was removed from ovaries in HBSS (GIBCO/Life Technologies). Ovaries 152 
were manually dispersed under a dissection microscope using 19 gauge needles in a total of 153 
500 µl of 10 mg/ml Collagenase IV (Sigma, Dorset, UK) in HBSS. The tissue/collagenase 154 
suspension was incubated in a thermomixer at 37°C, shaking at 1000 rpm for 10 min and 155 
pipetted up and down to ensure complete disaggregation of the tissue. Fifty µl of DNase I (7 156 
mg/ml HBSS; Sigma) was added to the suspension and incubated for a further 5 min, shaking 157 
at 37°C. The single cell suspension was then centrifuged at 600 g for 5 min and the cell pellet 158 
was washed twice with 1 ml HBSS; centrifuging between each wash. The cell pellet was then 159 
resuspended in 1 ml of DMEM (without phenol red) (GIBCO/Life Technologies) 160 
supplemented with 10% FCS, 2mM L-glutamine, 1X MEM Non-Essential Amino Acids 161 
(NEAA; all GIBCO/Life Technologies) and 1X penicillin/streptomycin/amphotericin 162 
(GIBCO/Life Technologies). The cell suspension was filtered through a 70 µm filter and the 163 
resulting filtrate centrifuged. The cell pellet was resuspended in 1.2 ml of culture medium. 164 
200 µl of the initial cell suspension was transferred to a separate fresh 1.5 ml tube and 165 
centrifuged. The cell pellet was washed in 1X phosphate-buffered saline (PBS), resuspended 166 
in 350 µl of buffer RLT (Qiagen) with 2-mercapthoethanol (Sigma Aldrich) and stored at -167 
80°C for RNA isolation (T0). The remaining cells were cultured in 2 wells of a 12-well plate 168 
at 37°C and 5% CO2 overnight. After 13-17 h, the cells were washed twice with culture 169 
medium and these washes were collected and centrifuged. The pellet was washed with PBS 170 
and resuspended in 350 µl of buffer RLT plus 2-mercapthoethanol and stored at -80°C for 171 
RNA isolation (S0). Fresh culture medium was added to each well and the cells were cultured 172 
further until confluent (P0 culture). Once the cell cultures were confluent, the cells were 173 
detached through trypsination. An aliquot of the cells was collected for RNA extraction. The 174 
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remaining cells were passaged into either a 6-well plate or 25 cm
2
 tissue culture flask. 175 
Passaging of cells and freezing down aliquots of cells in Bambanker
TM
 (Anachem, Luton, 176 
Beds, UK) freezing medium were continued for several passages. 177 
 178 
Screening for possible regulators of FBN3 expression in cultured bovine fetal fibroblasts 179 
 180 
Bovine fetal fibroblasts (n = 5 from weeks 13, 14, 17, 19 and 33 of gestation) previously 181 
stored in liquid nitrogen were thawed and 30,000 cells/well seeded in 24-well plates in 182 
DMEM/F12 medium containing 5% FCS, 1% penicillin and streptomycin sulphate and 0.1% 183 
fungizone, and incubated for 24 h at 38.5ºC and 5% CO2 until 60-70% confluent. The wells 184 
were washed with 1X PBS, and subsequently the different chemical treatments added. All 185 
treatments were prepared in DMEM/F12 medium containing 1% FCS, 1% penicillin and 186 
streptomycin sulphate, and 0.1% fungizone. After 18 h, the cells were harvested for RNA 187 
extraction by lysis in 500 µl Trizol
®
 (Ambion/Life Technologies) each and stored at -80°C. 188 
To limit the number of samples for the qRT-PCR, the treatments were used at concentrations 189 
previously reported in the literature instead of dose-response experiments for each of the 31 190 
agents (Table 1). 191 
 192 
Treatment of bovine fibroblast cultures with TGFβ1 and TGFβ-inhibitor SB431542 193 
 194 
Bovine fetal fibroblasts (n=5 for weeks 9-15 in the first trimester, n=6 for weeks 19-26 in the 195 
second trimester) were seeded at 30,000 cells/well in 24-well plates in DMEM/F12 medium 196 
containing 5% FCS, 1% penicillin and streptomycin sulphate and 0.1% fungizone, and 197 
incubated for 24 h at 38.5ºC and 5% CO2 until 60-70% confluent. After 24 h, the wells were 198 
washed with 1X PBS and immediately treated with 5 ng/µl or 20 ng/µl TGFβ-1 with or 199 
without the TGFβ inhibitor SB431542 (10 µM, dissolved in DMSO, Sigma-Aldrich), in 200 
DMEM/F12 medium containing 1% FCS, 1% penicillin and streptomycin sulphate and 0.1% 201 
fungizone. DMSO (0.78%), the vehicle for SB431542, was added to the control wells and the 202 
wells treated with TGFβ-1 alone. After 18 h, the cells were harvested for RNA.  203 
 204 
Culture of bovine ovarian tissue slices 205 
 206 
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Bovine fetal ovaries (n=4 12 to 18 weeks) were excised into two portions, one portion was 207 
stored at -80°C (0 h tissue) for subsequent RNA extraction and the second portion was 208 
cultured in DMEM/F12 medium containing 5% FCS, 1% penicillin and streptomycin 209 
sulphate and 0.1% fungizone, and incubated for 24 h at 38.5ºC and 5% CO2. After 24 h, the 210 
ovarian tissue slices were collected and frozen at -80°C for RNA extraction. 211 
 212 
Treatment of human fetal ovarian fibroblasts with TGFβ-1, activin-A and SB431542 213 
 214 
Human fetal ovarian fibroblasts (n=3, 15-17 weeks gestation) were cultured in 75 cm
2
 tissue 215 
culture flasks until sub-confluent. Cells were then seeded in culture medium in 6- or 12- well 216 
plates at 37°C for 7 hours. Once 70% confluent, the cells were washed and serum-starved 217 
overnight in culture medium containing only 1% FCS. The next day, the medium was 218 
replaced with fresh culture medium containing 1% FCS and the relevant treatments or 219 
vehicle; 5 ng/ml TGFβ-1, 100 ng/ml activin A, and 10 µM SB431542. The cells were 220 
incubated at 37°C for 24 h and then harvested for RNA extraction. 221 
 222 
RNA extraction and cDNA synthesis 223 
 224 
For our bovine study, the ovarian tissue samples previously frozen were homogenised in 1 ml 225 
of Trizol
®
 with 0.5 g of ceramic beads in homogenisation tubes using the Mo Bio Powerlyser 226 
24 (Mo Bio Laboratories Inc., Carlsbad, CA, USA). The cells previously harvested for RNA 227 
and the homogenised tissue samples underwent further treatment for RNA extraction as per 228 
manufacturer’s instructions (Ambion/Life Technologies). Using a Nanodrop 229 
spectrophotometer (NanoDrop 1000 3.7.1, Thermo Fisher Scientific, Inc., USA), the RNA 230 
concentrations were determined based on the 260 λ (wavelength) absorbance. All samples 231 
had a 260/280 λ absorbance ratio > 1.8 indicating sufficient RNA purity for analysis. 200 ng 232 
of each DNAse-treated RNA underwent cDNA synthesis as described in a previous study 233 
(Matti et al. 2010). 234 
For the human samples, RNA was extracted from cells using the RNeasy Micro Kit 235 
(Qiagen, Crawley, UK) with on-column DNase I digestion as per manufacturer’s instructions. 236 
After quantification on a Nanodrop spectrophotometer, reverse transcription was carried out 237 
using 200ng RNA/reaction with the Maxima First Strand cDNA synthesis kit (Thermo Fisher 238 
Scientific Inc, USA). 239 
 240 
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Quantitative real-time PCR 241 
 242 
Quantitative real-time PCR of the bovine samples for the target genes FBN1, FBN2 and 243 
FBN3 and the housekeeping gene 18S was performed using a Rotor-Gene 6000 series 1.7 244 
thermal cycler (Corbett Life Science, Concord, NSW, Australia). cDNA dilutions were 245 
amplified in 10 µl reactions containing 5 µl of Power SYBR™ Green PCR Master Mix 246 
(Applied Biosystems/Life Technologies), 0.1 µl each of reverse and forward primers 247 
(Geneworks; Table 4) respectively for the genes of interest, 1 µl of the 1:100 cDNA dilution 248 
(for the housekeeping gene 18S) or 1:10 cDNA dilution (for FBN1, FBN2, FBN3) and 3.6 µl 249 
of DEPC-treated water. PCR amplification of the cDNA samples was carried out in 250 
duplicates at 95°C for 15 sec, followed by 60°C for 60 sec for a total of 40 cycles. The Rotor-251 
Gene 6000 software (Q Series, Qiagen) was used to determine the cycle threshold (Ct) values 252 
at a threshold of 0.05 normalized fluorescence units. Gene expression was determined by the 253 
mean of 2
-∆Ct
, where ∆Ct represents the target gene Ct – 18S Ct.  The standard error of the 254 










.   256 
Gene expression in human fetal ovaries and ovarian cell cultures was analysed by 257 
qRT-PCR using the ABI7900 Fast system with SDS2.4 software (Life Technologies, Paisley, 258 
UK).and Brilliant III SYBR Green Master Mix (Agilent Technologies, Wokingham, UK), 259 
with melt curve analysis as described previously (Bayne et al. 2015). Primers used for the 260 
qRT-PCR are shown in Table 2.  261 
 262 
Statistical analyses 263 
 264 
All statistical calculations were performed using Microsoft Office Excel 2010 (Microsoft, 265 
Redmond, WA, USA) and GraphPad Prism version 6.00 (GraphPad Software Inc., La Jolla, 266 
CA, USA). For the treatment experiments on bovine and human samples, statistical 267 
comparisons of the ∆Ct data between the untreated control and the treatments for each fetal 268 
fibroblast sample were conducted using log transformed data where appropriate by ANOVA 269 
with Dunnett’s post-hoc test and a value of P<0.05 was considered significant. For the bovine 270 
ovarian tissue culture experiment, statistical comparisons of the ∆Ct data between the 0 h 271 
tissue and the 24 h cultured tissue for each fetal ovary sample were conducted by unpaired T-272 
tests and a value of P<0.05 was considered significant. 273 
 274 
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Screening for possible regulators of FBN3 278 
 279 
To identify possible regulators of FBN3, we treated bovine fetal ovarian fibroblasts (n = 5 280 
ovaries, each from 13, 14, 17, 19 and 33 weeks of gestation) with 31 different reagents (Table 281 
1) for 18 h and observed their effects on FBN3 expression (Fig. 1).  The range of treatments 282 
used included cAMP regulators, growth factors, steroid hormones, peptide hormones, 283 
prostaglandins and cytokines, previously shown to play roles in adult ovarian function, such 284 
as cell proliferation and extracellular matrix production. No substantial effects were seen in 285 
any individual culture and the data were therefore combined across the gestational ages for 286 
statistical analyses which showed that there were no significant differences in FBN3 287 
expression between the control and any of the treated cultures. Furthermore, we also 288 
observed that expression FBN3 in these cultures was very low. 289 
 290 
Treatment of bovine fetal fibroblasts with TGFβ-1 and TGFβ-inhibitor SB431542 291 
 292 
A partial dose response experiment was carried out using 5 or 20 ng/ml TGFβ-1 with or 293 
without the TGFβ-signalling inhibitor SB431542, which selectively inhibits the TGFβ 294 
superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 295 
(Inman et al. 2002a), using fetal ovarian fibroblast cultures (n = 5 ovaries from weeks 9-15 in 296 
first trimester, n = 6 ovaries from weeks 19-26 in the second trimester).  Gene expression 297 
analyses showed that the expression of FBN1 in fetal ovarian fibroblasts from 9-15 weeks of 298 
gestation was not significantly affected when these cells were treated with TGFβ-1 (Fig. 2). 299 
However, it was observed that compared to the untreated control, there was a significant 300 
increase in FBN1 expression in the TGFβ-1-treated 19-26 week fibroblasts, with the higher 301 
TGFβ-1 concentration causing a more significant increase in FBN1 expression. This effect of 302 
TGFβ-1 was prevented by the antagonist SB431542, which had no effect alone. TGFβ-1 did 303 
not cause a significant effect on FBN2 expression in the 9-15 week gestation cells (Fig. 2) but 304 
SB431542 caused a significant reduction in FBN2 expression, with or without TGFβ-1 (Fig. 305 
2). In later gestation TGFβ-1 stimulated FBN2 expression and SB431542 inhibited this 306 
stimulation, similarly to the effect on FBN1 expression. None of the treatments significantly 307 
affected FBN3 expression in fibroblast cultures of either gestational age (Fig. 2). 308 
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Expression of FBN1-3 in bovine fetal ovarian tissue  310 
 311 
We then measured expression levels of fibrillin genes in fetal ovarian tissue slices before (0 312 
h) and after culturing for 24 h (n = 1 ovary from 12 weeks of gestation and n = 3 ovaries from 313 
weeks 16-18). There were no significant differences (P > 0.05) in FBN1 and FBN2 314 
expression respectively between the 0 h ovarian tissue and the ovarian tissue cultured for 24 h 315 
(Fig. 3). However, we observed a significant decline in FBN3 expression by 24 h. 316 
 317 
Expression of FBN1-3 in human fetal ovarian cells 318 
 319 
The expression levels of FBN1-3 were analysed in disaggregated human fetal ovarian tissue 320 
(n = 4 ovaries from 9-17 weeks of gestational age) before culture, in adherent ovarian 321 
fibroblasts before the first passage and up to the eighth cell passage. FBN1 and FBN2 322 
expression increased in all cultures across passages (Fig. 4). FBN3 was expressed higher in 323 
the disaggregated cells of 9 week old fetal ovary compared to later gestation fetal ovaries 324 
(Fig. 4). However the ovarian cells of all fetal ovaries showed a dramatic decline in FBN3 325 
expression in culture and a loss of FBN3 expression after the first passage. 326 
 327 
TGFβ-1, activin A and SB431542 treatment of human fetal ovarian cells 328 
 329 
Human fetal ovarian fibroblasts (n = 3 ovaries from 15-17 weeks gestation) were treated with 330 
5 ng/ml TGFβ-1, 100 ng/ml activin A and 10 µM SB431542 separately. TGFB1-3, LTBP1-4, 331 
FBN1-3, AR, INHBA, HTRA1 and BDNF expression levels were subsequently measured. 332 
SB431542 treatment significantly lowered TGFB1, LTBP2, TGFBI, INHBA and BDNF 333 
expression, whereas TGFβ-1 treatment significantly reduced AR expression (Fig. 5). None of 334 
the treatments significantly affected TGFB2-3, LTBP1, LTBP3-4, FBN1-2, and HTRA1 335 
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In this study we investigated the regulation of fibrillins and related TGFβs and latent TGFβ 341 
binding proteins in vitro using bovine and human fetal ovaries under different culture 342 
conditions: monolayer culture, passaging of these monolayer cultures and culture of pieces of 343 
tissue. We initially carried out a screen for possible regulators of FBN3. The effects of TGFβ 344 
and its pathway inhibitor SB431542 were examined in more detail and the effects on all 345 
fibrillins were examined.  In humans the effects of these and activin were also examined in 346 
detail.  A consistent observation was that during culture FBN3 was down regulated and FBN1 347 
was up regulated, as occurs in vivo with increasing gestation (Hatzirodos et al. 2011).  348 
To date, there has only been one study that has investigated the effects of TGFβ 349 
signalling on the expression of fibrillin genes in fetal tissues. This study found that TGFβ-1 350 
increased FBN1 and FBN2 expression in murine fetal skin (Samuel et al. 2003). Since a 351 
murine model was used for that study, an examination of the expression of FBN3 was not 352 
possible as this gene is inactivated in mice (Corson et al. 2004). In adult fibroblasts TGFβ-1 353 
was shown to increase FBN1 and FBN2 expression (Samuel et al. 2003) and the involvement 354 
of the TGFβ superfamily is well characterised in ovarian follicle development (Knight & 355 
Glister 2006).  We therefore examined the effects of TGFβ-1 on expression of the fibrillin 356 
genes. In the bovine study, we found that treatment with TGFβ-1 caused a significant 357 
increase in FBN1 and FBN2 expression in the second trimester fibroblasts.  These results 358 
suggest that in the bovine, TGFβ-1 regulation of the expression of FBN1 and FBN2 only 359 
becomes active as development progresses. However, TGFβ-1 treatment did not affect FBN1 360 
and FBN2 expression in cultured human fetal ovarian fibroblasts at 15-17 weeks gestation. 361 
FBN2 has different expression profiles in the bovine and human both during gestation and in 362 
the adult ovaries (Hatzirodos et al. 2011), suggesting differential regulation in these species. 363 
Furthermore, it appears that TGFβ-1 regulates FBN2 expression differently in the bovine and 364 
human later in gestation.  365 
We also examined human fetal ovarian fibroblasts from later gestation when 366 
steroidogenic enzymes are expressed (Fowler et al. 2011). We observed that TGFβ-1 367 
treatment caused a significant decrease in the expression of the androgen receptor gene (AR). 368 
There are no previous studies that have investigated the effects of TGFβ directly on AR 369 
expression. However, it is known that interaction of Smad3, a mediator of intracellular TGFβ 370 
signalling, with the androgen receptor represses AR-mediated transcription, but the exact 371 
mechanisms of this repression are not well understood (Kang et al. 2001; Chipuk et al. 2002). 372 
Treatment of monkey kidney cells and human prostate cells with TGFβ-1 caused a reduction 373 
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in AR-mediated transcription as indicated by luciferase reporter activity in these cells (Hayes 374 
et al. 2001). The findings of our study suggest that TGFβ signalling may repress AR-375 
dependent transcription by inhibiting expression of the androgen receptor itself. On the other 376 
hand, we also observed significant reductions in the expression of the TGFB1, LTBP2, 377 
TGFBI, and INHBA genes when the human fetal ovarian fibroblasts were treated with the 378 
TFGβ antagonist SB431542. SB431542 selectively inhibits TGFβ type I receptors, activin-379 
like receptor kinase 4, 5 and 7 (ALKs 4, 5 and 7) (Inman et al. 2002a). Therefore, ALK5 380 
remains inactive (Callahan et al. 2002) and unable to phosphorylate Smads 2 and 3 (Callahan 381 
et al. 2002; Inman et al. 2002a) and the classical TGFβ/smad pathway is disrupted (Heldin et 382 
al. 1997; Inman et al. 2002b; Derynck & Zhang 2003). TGFβ-1 treatment causes a small and 383 
non-significant increase in the expression of these genes thus the effect of SB431542 is likely 384 
to reflect antagonism of stimulation by endogenous TGFβ signalling. Likewise the reduction 385 
in BDNF expression with SB431542 treatment suggests that endogenous TGFβ signalling is 386 
capable of stimulating BDNF expression in these cultured fibroblasts. 387 
In culture of bovine fetal fibroblasts from the first trimester, SB431542 either alone or 388 
in combination with TGFβ-1 caused a significant decrease in FBN2 expression compared to 389 
the control even though TGFβ-1 had no effect on these fibroblasts. Therefore, as with the 390 
human cell experiments, we speculate that SB431542 is inhibiting endogenous TGFβ 391 
signalling via the TGFβ type I and II receptors which is stimulatory of FBN2 expression. The 392 
TGFβ superfamily ligands that bind to these receptors include TGFβs, activins, nodal and 393 
GDF8 (myostatin) (Heldin et al. 1997; Reissmann et al. 2001; Derynck & Zhang 2003; 394 
Rebbapragada et al. 2003). Currently, we have not identified which of these endogenous 395 
ligands are involved. On the other hand, in the second trimester bovine fibroblasts, the 396 
expression levels of FBN1 and FBN2 were similar to the control when SB431542 in 397 
combination with TGFβ-1 was present in these cultures. Since we observed that TGFβ-1 398 
increased the expression of FBN1 and FBN2 in these fibroblasts, these observations suggest 399 
that SB431542 is alleviating the effects of exogenous TGFβ-1, with no evidence of 400 
stimulation of the expression of these genes by endogenous TGFβ. Overall, our observations 401 
show that FBN1 and FBN2 are differentially regulated in both the bovine and human ovary.  402 
To date, there have not been any studies that have investigated the effect of activin A 403 
on the gene expression of fibrillins. However, previous studies have shown that activin A is 404 
capable of causing an increase in the proliferation of human lung fibroblasts (Heeren et al. 405 
2015) as well as promoting proliferation of cultured rat renal interstitial fibroblasts and 406 
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increasing the expression of type I collagen (Yamashita et al. 2004). We have observed that 407 
activin A did not affect the expression of FBN1 or FBN2 or the other TGFβ-associated genes 408 
examined in our human samples. The levels of FBN3 expression in the treated human fetal 409 
ovarian fibroblasts cultures were undetectable. 410 
The fetal ovary consists of a mixture of cell types and interactions between 411 
fibroblasts, GREL cells, pregranulosa/ granulosa cells and germ cells might be required to 412 
maintain FBN3 expression. The other cell types in the ovary may also be producing factors 413 
required by fibroblasts to stimulate FBN3 expression. Thus we carried out tissue culture 414 
experiments, but even a short-term culture (24 h) of bovine fetal ovarian tissue sections, 415 
which represent a cross-section of the three-dimensional ovarian structure containing all cell 416 
types and its extracellular matrix, showed a decline in the expression of FBN3. Similarly, we 417 
observed a drastic decline in FBN3 expression but an increase in FBN1 and FBN2 expression 418 
in the cultured human fetal ovarian fibroblasts, consistent with their developing a more 419 
mature phenotype in culture.  This indicates very stringent and possibly complex regulation 420 
of FBN3 expression in vivo, which is not maintained in vitro, limiting our ability to study the 421 
expression of this gene.  422 
A previous study showed that ovarian FBN2 and FBN3 are fetal fibrillins (Hatzirodos 423 
et al. 2011). FBN3 is initially expressed highly and then begins to decline at the end of the 424 
first trimester and FBN2 declines sometime between the fetal stages and adulthood at least in 425 
human (Hatzirodos et al. 2011). FBN1 persists through fetal ovary development and is 426 
increased in the adult ovary (Hatzirodos et al. 2011) - it is an adult fibrillin. These data 427 
therefore imply that the three fibrillin genes have independent regulatory mechanisms to 428 
account for their different expression profiles in the bovine and human. This is also supported 429 
by the study of Davis et al. (2014) which found that there was little overlap in the 430 
transcription factor motifs present on the human FBN3 promoter and those of FBN1 and 2 431 
promoters, suggesting that these genes are differentially regulated and differentially 432 
expressed (Davis et al. 2014).  433 
In summary, FBN3 expression is rapidly reduced in both cell and tissue culture, and 434 
was not maintained or stimulated by a range of growth factors. This study has also shown that 435 
in the bovine, there is differential regulation of FBN1 and FBN2 between the early and later 436 
stages of gestation which is partially mediated through the signalling pathways involving 437 
either ALK 4, 5 or 7. TGFβ regulates its own signalling both directly through TGFβ 438 
expression, and through regulation of expression of other binding proteins such as LTBP2.  439 
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These data therefore demonstrate that the regulation of TGFβ signalling appears to change 440 
during fetal ovarian development.  441 
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Table 1 Treatments for cultured bovine fetal ovarian fibroblasts. 
Category Treatments Concentration Distributor 
Hormones Dihydroxytestosterone 100 ng/ml Sigma-Aldrich 
Estradiol 100 ng/ml Sigma-Aldrich 
Progesterone 100 ng/ml Sigma-Aldrich 
Testosterone 100 ng/ml Sigma-Aldrich 
Prolactin 1 µg/ml National Institute of Diabetes and Digestive and 
Kidney Diseases – National Institutes of Health 
Relaxin 16.7 nM From Dr. Ross Bathgate – University of Melbourne, 
Australia 
Insulin-like protein 3  100 ng/ml From Dr. Ross Bathgate – University of Melbourne, 
Australia 
Müllerian-inhibiting substance  10 ng/ml 
 
Biogen Idec Australia Pty Ltd., North Ryde, NSW, 
Australia 
 Insulin-like growth factor 1  30 ng/ml GroPep Bioreagents Pty Ltd., Thebarton, SA, 
Australia 
Prostaglandins Prostaglandin E2 1 µM Upjohn Company, Michigan, USA 
Prostaglandin F2α 1 µM Upjohn Company 
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Cytokines Interleukin 1 beta  50 ng/ml R&D Systems, distributed by Bio-Scientific Pty Ltd., 
Gymea, NSW, Australia 
Tumour necrosis factor 10 ng/ml R&D Systems 






Vitamin Retinoic acid 3 µg/ml Sigma-Aldrich 
Growth 
Factors 
Activin A 100 ng/ml R&D Systems 
Basic fibroblast growth factor  100 ng/ml Roche Australia Pty Ltd., Thebarton, SA, Australia 
Bone morphogenetic protein 6  100 ng/ml R&D Systems 
Epidermal growth factor  10 ng/ml 
 
Boehringer Ingelheim Pty Ltd., North Ryde, NSW, 
Australia 
Fibroblast growth factor 7  10 ng/ml R&D Systems 
Fibroblast growth factor 9  30 ng/ml R&D Systems 
Platelet-derived growth factor  10 ng/ml R&D Systems 
Bone morphogenetic protein 15  100 ng/ml R&D Systems 
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Connective tissue growth  25 ng/ml Invitrogen/Life Technologies 
Stem cell factor  100 ng/ml R&D Systems 
Transforming growth factor beta 1  10 ng/ml R&D Systems 
Vascular endothelial growth factor  10 ng/ml R&D Systems 
Glial-derived factor 9  100 ng/ml R&D Systems 
Glial-cell derived neurotrophic factor  100 ng/ml R&D Systems 
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Table 2 List of genes and primers used for qRT-PCR.  
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Fibrillin 2 FBN2 Human 7545-7646 TCCAGTCAAGTTCTT TGCGACTACTGGA NM_001999 
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Figure Legends 1 
 2 
Figure 1 Expression of FBN3 in bovine fetal fibroblasts from different gestational ages 3 
cultured in the presence of 31 different chemical agents for 18 hours. The data are shown as 4 
mean ± SEM of fold change in FBN3 expression relative to the untreated control (n = 5 5 
ovaries, each from 13, 14, 17, 19 and 33 weeks of gestation, respectively).  6 
 7 
Figure 2 Expression of FBN1-3 in bovine fetal fibroblasts from the first and second trimester 8 
of gestation cultured in the presence of 5 and 20 ng/ml TGFβ-1 with and without 10 µM 9 
SB431542 for 18 hours. The data are shown as mean ± SEM of fold change in FBN1-3 10 
expression relative to the untreated control (n = 5 ovaries from weeks 9-15 in the first 11 
trimester, n = 6 ovaries from weeks 19-26 in the second trimester). Significantly different 12 
results for qRT-PCR were determined by one-way ANOVA with Dunnet’s post-hoc test. All 13 
values which were statistically different from the control are indicated by asterisk symbols in 14 
the graphs. *P < 0.05, **P < 0.01, significant differences. 15 
 16 
Figure 3 Expression of FBN1-3 in bovine fetal ovarian tissue slices before and after 24 h 17 
culture. The data are shown as the mean ± SEM of FBN1-3 expression relative to 18S (n = 1 18 
ovary from 12 weeks of gestation and n = 3 ovaries from weeks 16-18). Significantly 19 
different results for qRT-PCR were determined by unpaired T-tests.  All values which were 20 
statistically different are indicated by asterisk symbols in the graphs. *P < 0.05, **P < 0.01, 21 
significant differences. 22 
 23 
Figure 4 Expression levels of FBN1-3 (pmol/nmol RPL32) in human fetal ovarian somatic 24 
cell/ fibroblast cultures from different gestational ages from tissue digestion up to the eighth 25 
passage. T0 represents disaggregated ovarian tissue before culture and P0 represents adherent 26 
ovarian cells before the first passage.  The different coloured symbols represent cells from 27 
single ovaries at different gestational ages: (*) represents a 9 week ovary, () represents a 15 28 
week ovary, (•) represents a 16 week fetal ovary, and () represents a 17 week fetal ovary. 29 
 30 
Figure 5 Expression levels of TGFB1-3, LTBP1-4, FBN1-2, TGFBI, AR, INHBA, HTRA1, 31 
and BDNF in primary human fetal ovarian fibroblast cultures in the presence or absence of 5 32 
ng/ml TGFβ-1, 100 ng/ml activin A and 10 µM SB431542 for 24 hours. The data shown are 33 
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mean ± SEM of target gene expression relative to the untreated control from 15-17 weeks 34 
gestation human fetal ovarian fibroblast cultures (n = 3 ovaries). Significantly different 35 
results for qRT-PCR were determined by one-way ANOVA with Dunnet’s post-hoc test. All 36 
values which were statistically different from the control are indicated by asterisk symbols in 37 
the graphs. *P < 0.05, **P < 0.01, significant differences. 38 
 39 
 40 
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